新型抗结核药物制剂研究进展

结核病(tuberculosis，TB)是一种由结核分枝杆菌(Mycobacterium tuberculosis，MTB)引起的慢性传染病，它积聚在各个器官，特别是肺部。目前临床上常用的抗结核药物主要以胶囊剂、片剂或注射剂为主，但这些常规剂型往往难以在结核病核心病灶区域有效分布，药物通过全身循环向其他组织和器官非特异性分布，导致局部药物浓度低，易产生不良反应，进而影响抗结核药的治疗效果。微球、脂质体、纳米粒等新剂型能够选择性地将药物浓集于结核病变部位，从而达到降低药物不良反应，提高患者依从性的目的。因此，本文旨在对抗结核药物新剂型的相关研究进行综述。

Advance of new Anti-tuberculosis drug preparation

Tuberculosis(TB) is a chronic infectious disease caused by Mycobacterium tuberculosis(MTB). It can accumulate multiple organs, of which tuberculosis is the most common attack on the lungs. At present, the commonly used anti tuberculosis drugs are mainly oral tablets, capsules or injections, but these conventional formulations are often difficult to distribute effectively in the core lesion area of the tuberculosis, so that the drugs are distributed nonspecific to other tissues and organs through the circulation of the body, resulting in low local drug concentration and easy to produce adverse reactions, thus affecting the therapeutic effect of antitubercular drugs. Microspheres, liposomes, nanoparticles and other new dosage forms can selectively concentrate drugs on tuberculosis lesions, thereby reducing the side effects of drugs and improving patient compliance. Therefore, this article aimed to provide a comprehensive review of the correlation research on new formulations of tuberculosis drugs.